ArticleVirchows Archiv : an international journal of pathology2025
Melanoma microsatellites exhibit a metastatic signature by spatial transcriptomics and overexpress mediators of immune evasion.
Article in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microsatellites in melanoma are physically separate from the primary tumor, are hypothesized to arise by lymphovascular invasion similar to other metastases, and have not been previously studied at the molecular level. We compared gene expression in microsatellites with the matched primary melanoma in two patients using spatial transcriptomics. We identified recurrently altered genes in microsatellites contributing to vascular invasion (ITGA4, MCAM), survival in the circulation (CXCL8, PDGFRB, CDH1), vascular exit (ITGB2), survival at metastatic sites (C3, TGBFI), matrix remodeling (MMP9, VCAN, FN1, BGN), and angiogenesis (EMILIN2). Gene set enrichment analysis confirmed a metastatic signature in comparison to genes upregulated and downregulated in distant melanoma metastases, and identified pathway enrichment for NFKB, CDH1, and ZEB1 signaling. Microsatellites exhibited increased host immune responses and four recurrently overexpressed mediators of immune evasion were present (PAEP, GDF15, CD74, HLA-DRA) implying selection pressure from the increased immune response. Seven additional non-recurrent mediators of immune evasion were identified in microsatellites, overexpressed up to 58-fold in microsatellites. PAEP was 275-fold and 25-fold overexpressed, respectively, in microsatellites in two cases. We studied PAEP protein expression by immunohistochemistry in a larger group of 12 and found overexpression in microsatellites in five of 12 patients. PAEP was detected by immunohistochemistry in a microsatellite and also in a subclone within its primary, raising the possibility that the immunostain identifies the subclone in the primary responsible for the microsatellite. These preliminary findings suggest that melanoma microsatellites are true metastases at the level of gene expression, accounting for the sharply increased risk of disease progression in patients with microsatellites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.